- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02548390
Study of Intravenous RXDX-107 in Patients With Solid Tumors
April 24, 2019 updated by: Hoffmann-La Roche
A Phase 1/1b, Multicenter, Open-Label Study of Intravenous RXDX-107 in Adult Patients With Locally Advanced or Metastatic Solid Cancer
This is an open-label, Phase I/Ib, dose escalation study of intravenous RXDX-107 administered to subjects with advanced solid tumors.
The study is designed to explore the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RXDX-107 and to define a recommended Phase 2 dose (RP2D)
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
70
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Sarasota, Florida, United States, 34232
- Florida Cancer Specialists
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins Medical Institute
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed relapsed or refractory locally advanced or metastatic solid cancer for whom no standard therapy is considered appropriate, or for whom standard therapy is considered intolerable.
- >18 years of age.
- ECOG performance status of 0 or 1.
- Life expectancy of at least 3 months.
Received the last dose of previous treatment / therapy before Day 1 of cycle 1:
- 28 days for cytotoxic chemotherapy, immunotherapy, whole brain radiotherapy, anticonvulsive therapy, stereotactic radiosurgery and major surgery
- 42 days for nitrosureas, mitomycin C, and liposomal anthracycline
- 14 days for non-cytotoxic cancer therapies and radiotherapy
- Recovered from all toxic effects (excluding alopecia) of any prior anti-cancer therapy to Grade ≤ 1 or to the baseline laboratory values.
- Adequate organ function and baseline laboratory values
- Women of childbearing potential must have a negative serum pregnancy
Phase 1b: Patient must have measurable disease
Exclusion Criteria:
- Receiving other experimental therapy
- Known symptomatic brain mets or leptomeningeal involvement
- Myocardial infarction in the previous 12 weeks. Active ischemia or any other uncontrolled cardiac condition such as angina pectoris, significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, or CHF.
- Another concurrent illness which would preclude study conduct and assessment, uncontrolled: medical condition, active infection, risk of bleeding, diabetes mellitus, or pulmonary disease, or alcoholic liver disease, or primary biliary cirrhosis.
- Malignancy within 3 years or active disease requiring treatment other than the target cancer. The exceptions are prostate cancer (Gleason grade < 6 with normalized PSA levels), treated in situ cervical, breast carcinoma, squamous or basal cell skin cancer.
- Any condition that may compromise the ability to give written informed consent or to comply with the study protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RXDX-107
|
Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts.
Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined.
An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed.
Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: Safety profile of RXDX-107 as characterized by Adverse Events, ECG and laboratory abnormalities
Time Frame: Approx. 1 year
|
AEs, ECG and Labs assessed according to NCI CTCAE V4.0
|
Approx. 1 year
|
Phase 1: Maximum observed plasma drug concentration (Cmax)
Time Frame: Approx. 1 year
|
Plasma concentrations obtained following the dose on Day 1 (and from the dose on Day 2 in patients receiving the Day 1 and Day 2 schedule)
|
Approx. 1 year
|
Phase 1: Time to Cmax, by inspection (tmax)
Time Frame: Approx. 1 year
|
Plasma concentrations obtained following the dose on Day 1 (and from the dose on Day 2 in patients receiving the Day 1 and Day 2 schedule)
|
Approx. 1 year
|
Phase 1: Area under the drug concentration by time curve (AUC)
Time Frame: Approx. 1 year
|
From time 0 to the time of the last detectable plasma concentration (AUC0-t)
|
Approx. 1 year
|
Phase 1: Apparent plasma terminal elimination rate constant (λz) and associated terminal half life (t½)
Time Frame: Approx. 1 year
|
Plasma concentrations obtained following the dose on Day 1 (and from the dose on Day 2 in patients receiving the Day 1 and Day 2 schedule)
|
Approx. 1 year
|
Phase 1: Plasma clearance (CL)
Time Frame: Approx. 1 year
|
Plasma concentrations obtained following the dose on Day 1 (and from the dose on Day 2 in patients receiving the Day 1 and Day 2 schedule)
|
Approx. 1 year
|
Phase 1: Volume of distribution (Vz)
Time Frame: Approx. 1 year
|
Plasma concentrations obtained following the dose on Day 1 (and from the dose on Day 2 in patients receiving the Day 1 and Day 2 schedule)
|
Approx. 1 year
|
Phase 1: Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D)
Time Frame: Approx. 6 months
|
Approx. 6 months
|
|
Phase 1b: Confirm RP2D
Time Frame: Approx. 1 year
|
Number of participants with Treatment-related AEs, Labs changes from baseline, and QTc interval changes from baseline assessed according to NCI CTCAE V4.0, concomitant medication usage, including all supportive care provided, and preliminary anti-tumor activity per RECIST v1.1 as assessed by Investigator
|
Approx. 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antitumor activity of RXDX-107 as measured by Objective Response Rate (ORR)
Time Frame: Approx. 1 year
|
Per RECIST v1.1 as assessed by Investigator
|
Approx. 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Actual)
September 1, 2016
Study Completion (Actual)
September 1, 2016
Study Registration Dates
First Submitted
September 9, 2015
First Submitted That Met QC Criteria
September 10, 2015
First Posted (Estimate)
September 14, 2015
Study Record Updates
Last Update Posted (Actual)
April 25, 2019
Last Update Submitted That Met QC Criteria
April 24, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- RXDX-107-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
Clinical Trials on RXDX-107
-
AstraZenecaActive, not recruitingPrimary Aldosteronism | HyperaldosteronismUnited States
-
Dow Pharmaceutical SciencesCompletedAcne VulgarisUnited States, Canada
-
AstraZenecaCompletedHypertensionUnited States
-
AstraZenecaCompletedStudy to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal FunctionHypertensionUnited States
-
Dow Pharmaceutical SciencesCompletedAcne VulgarisUnited States
-
AstraZenecaCompletedHypertensionUnited States
-
Hoffmann-La RocheTerminatedAdvanced or Metastatic Solid TumorsUnited States
-
Precision Life Sciences GroupCompletedGlioblastoma MultiformeUnited States
-
AstraZenecaParexelActive, not recruitingChronic Kidney Diseases | Uncontrolled HypertensionUnited States
-
AstraZenecaCompletedHypertensionUnited States